Molecular Insight hires new vice presidents

May 31, 2005

Molecular Insight Pharmaceuticals of Cambridge, MA, has appointed James Wachholz as vice president, regulatory affairs and quality assurance, and Joshua Hamermesh as vice president, commercial and business development.

Wachholz most recently served as chief regulatory officer of Accentia Biopharmaceuticals. Hamermesh comes to the radioisotope imaging developer from Genzyme Corporation.

By AuntMinnie.com staff writers
June 1, 2005

Related Reading

Molecular Insight raises $28 million, June 1, 2005

Molecular Insight, University of Maryland get NIH grant, August 27, 2004

Copyright © 2005 AuntMinnie.com

Pluvicto Spect Ct Response Thumbnail

SPECT/CT predicts treatment response in Pluvicto patients

November 1, 2024

New! Imaging Life Issue 20 now available

New! Imaging Life Issue 20 now available

November 5, 2024

Ask cardiac PET patients how much they exercise, study suggests

October 30, 2024

2024 10 28 Meningioma Thumbnail

Intraarterial PRRT safe in patients with meningioma

October 28, 2024

SPECT/CT predicts treatment response in Pluvicto patients

SPECT/CT scans taken just four hours after patients begin Lu-177 PSMA-617 treatment can help assess treatment responses.

November 1, 2024

Pluvicto Spect Ct Response Thumbnail

FCH-PET emerging in patients with hyperparathyroidism

F-18 fluorocholine (FCH) PET/CT appears to be an effective first-line imaging method in patients with primary hyperparathyroidism.

October 31, 2024

Hyperparathyroidism

Ask cardiac PET patients how much they exercise, study suggests

Exercise activity is an independent predictor of events such as heart attacks in patients undergoing stress PET myocardial perfusion imaging.

October 30, 2024

Intraarterial PRRT safe in patients with meningioma

Intraarterial peptide receptor radionuclide therapy (PRRT) is a safe and effective alternative to intravenous PRRT in patients with advanced meningioma.

October 28, 2024

2024 10 28 Meningioma Thumbnail

PSMA-PET provides long-term benefits

Prostate-specific membrane antigen (PSMA) PET imaging could improve the length and quality of life for patients with recurrent prostate cancer.

October 24, 2024

Prostate Imaging2

New PET tracer improves detection of insulinomas

A new PET/CT radiotracer that detects insulinomas could eliminate the need for other diagnostic procedures in a vast majority of patients.

October 21, 2024

Glp 1 R Pet 67169a712e569 Thumbnail

Tc-99m shortage expected into November

The delayed restart of a nuclear research reactor in the Netherlands is expected to cause supply shortages of technetium-99m (Tc-99m) into November.

October 18, 2024

FAPI-PET shows value in staging lung cancer patients

Fibroblast activation protein inhibitor (FAPI) PET/CT shows excellent diagnostic accuracy for detecting lymph node metastases in lung cancer patients

October 17, 2024

New guidelines cover theranostics for brain tumors

The use of somatostatin receptor PET imaging and therapy in meningiomas is on the rise.

October 14, 2024

NNSA's Mo-99 program: A bumpy ride

Last year was a bumpy ride for a U.S. initiative to secure domestic supplies of molybdenum-99 (Mo-99).

October 10, 2024

FES-PET improves management of breast cancer patients

PET/CT imaging with F-18 fluroestradiol (FES) can play a significant role in helping clinicians make treatment decisions in patients with recurrent or metastatic breast cancer

October 7, 2024

2024 10 07 Fes Pet Thumbnail

What impact will flurpiridaz F-18 have on heart care?

Seventeen years was all it took for flurpiridaz F-18 to reach the market, with the first patient injected with the PET imaging agent in November, 2007.

October 4, 2024

Page 1 of 598